Skip to main content

In Vivo Monitoring the Process of Tumor Growth, Metastasis and Bacterial Infection Expressing GFP via Real-Time Optical Imaging

Buy Article:

$107.14 + tax (Refund Policy)

Noninvasive molecular fluorescence imaging in vivo which combines Optical imaging with genetic marker technology can real time monitor the development of tumor, through the use of human adenoid cystic carcinoma cell (ACC-M) and lung carcinoma cells SPC-A1 were thansfected by green fluorescent protein (GFP). This study established three types of model: Experimental metastases by tail vein injection of ACC-M-EGFP, spontaneous metastases by abdomen subcutaneous injection of SPC-A1-EGFP and subcutaneous tumor growth by subcutaneous injection of SPC-A1-EGFP. Tumor-bearing mice were viewed with whole-body fluorescent imaging system. The results showed that growth and metastasis of tumor were visualized clearly with this system. While this simple, non-intrusive technique can show in great detail the temporal behavior of the infectious process of red fluorescent protein (DsRed2-expressing bacteria from outside intact infected animals. Therefore, this study provides a platform for monitoring tumor growth and metastasis and evaluating efficacy of antitumor drugs in vivo.

Keywords: BACTERIA; GREEN FLUORESCENT PROTEIN (GFP); OPTICAL IMAGING; RED FLUORESCENT PROTEIN (DSRED2); TUMOR

Document Type: Research Article

Publication date: 01 February 2013

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content